ango-20210831
false2022Q10001275187--05-31trueP2Yus-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrent00012751872021-06-012021-08-310001275187us-gaap:CommonStockMember2021-06-012021-08-310001275187ango:PreferredStockPurchaseRightsMember2021-06-012021-08-31xbrli:shares00012751872021-09-28iso4217:USD00012751872020-06-012020-08-31iso4217:USDxbrli:shares00012751872021-08-3100012751872021-05-3100012751872020-05-3100012751872020-08-310001275187us-gaap:CommonStockMember2021-05-310001275187us-gaap:AdditionalPaidInCapitalMember2021-05-310001275187us-gaap:RetainedEarningsMember2021-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-05-310001275187us-gaap:TreasuryStockMember2021-05-310001275187us-gaap:RetainedEarningsMember2021-06-012021-08-310001275187us-gaap:CommonStockMember2021-06-012021-08-310001275187us-gaap:AdditionalPaidInCapitalMember2021-06-012021-08-310001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2021-06-012021-08-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2021-06-012021-08-310001275187us-gaap:RestrictedStockUnitsRSUMember2021-06-012021-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-012021-08-310001275187us-gaap:CommonStockMember2021-08-310001275187us-gaap:AdditionalPaidInCapitalMember2021-08-310001275187us-gaap:RetainedEarningsMember2021-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-08-310001275187us-gaap:TreasuryStockMember2021-08-310001275187us-gaap:CommonStockMember2020-05-310001275187us-gaap:AdditionalPaidInCapitalMember2020-05-310001275187us-gaap:RetainedEarningsMember2020-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-05-310001275187us-gaap:TreasuryStockMember2020-05-310001275187us-gaap:RetainedEarningsMember2020-06-012020-08-310001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2020-06-012020-08-310001275187us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2020-06-012020-08-310001275187us-gaap:RestrictedStockUnitsRSUMember2020-06-012020-08-310001275187us-gaap:CommonStockMember2020-06-012020-08-310001275187us-gaap:AdditionalPaidInCapitalMember2020-06-012020-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-012020-08-310001275187us-gaap:CommonStockMember2020-08-310001275187us-gaap:AdditionalPaidInCapitalMember2020-08-310001275187us-gaap:RetainedEarningsMember2020-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-08-310001275187us-gaap:TreasuryStockMember2020-08-310001275187ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember2021-07-272021-07-270001275187ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember2021-07-270001275187us-gaap:TechnologyBasedIntangibleAssetsMemberango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember2021-07-272021-07-270001275187ango:EndovascularTherapiesMembercountry:US2021-06-012021-08-310001275187us-gaap:NonUsMemberango:EndovascularTherapiesMember2021-06-012021-08-310001275187ango:EndovascularTherapiesMember2021-06-012021-08-310001275187ango:EndovascularTherapiesMembercountry:US2020-06-012020-08-310001275187us-gaap:NonUsMemberango:EndovascularTherapiesMember2020-06-012020-08-310001275187ango:EndovascularTherapiesMember2020-06-012020-08-310001275187country:USango:VascularAccessMember2021-06-012021-08-310001275187us-gaap:NonUsMemberango:VascularAccessMember2021-06-012021-08-310001275187ango:VascularAccessMember2021-06-012021-08-310001275187country:USango:VascularAccessMember2020-06-012020-08-310001275187us-gaap:NonUsMemberango:VascularAccessMember2020-06-012020-08-310001275187ango:VascularAccessMember2020-06-012020-08-310001275187country:USango:OncologyMember2021-06-012021-08-310001275187us-gaap:NonUsMemberango:OncologyMember2021-06-012021-08-310001275187ango:OncologyMember2021-06-012021-08-310001275187country:USango:OncologyMember2020-06-012020-08-310001275187us-gaap:NonUsMemberango:OncologyMember2020-06-012020-08-310001275187ango:OncologyMember2020-06-012020-08-310001275187country:US2021-06-012021-08-310001275187us-gaap:NonUsMember2021-06-012021-08-310001275187country:US2020-06-012020-08-310001275187us-gaap:NonUsMember2020-06-012020-08-310001275187ango:MedTechMember2021-06-012021-08-310001275187ango:MedTechMember2020-06-012020-08-310001275187ango:MedDeviceMember2021-06-012021-08-310001275187ango:MedDeviceMember2020-06-012020-08-310001275187srt:MinimumMember2021-06-012021-08-310001275187srt:MaximumMember2021-06-012021-08-31xbrli:pureango:unit00012751872020-12-312020-12-310001275187ango:ProductTechnologiesMember2021-08-310001275187us-gaap:CustomerRelationshipsMember2021-08-310001275187us-gaap:TrademarksMember2021-08-310001275187us-gaap:LicenseAgreementTermsMember2021-08-310001275187ango:ProductTechnologiesMember2021-05-310001275187us-gaap:CustomerRelationshipsMember2021-05-310001275187us-gaap:TrademarksMember2021-05-310001275187us-gaap:LicenseAgreementTermsMember2021-05-310001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-06-030001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-06-032019-06-030001275187us-gaap:BaseRateMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-06-012021-08-310001275187us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2021-06-012021-08-310001275187srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-06-012021-08-310001275187us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-06-012021-08-310001275187us-gaap:LineOfCreditMember2021-06-012021-08-310001275187srt:MinimumMemberus-gaap:LineOfCreditMember2021-06-012021-08-310001275187srt:MaximumMemberus-gaap:LineOfCreditMember2021-06-012021-08-31ango:covenant0001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-06-012021-08-310001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-08-310001275187ango:A2020StockAndIncentiveAwardPlanMember2021-08-310001275187ango:EmployeeStockPurchasePlanMember2021-08-310001275187us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-08-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-08-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-08-310001275187us-gaap:FairValueMeasurementsRecurringMember2021-08-310001275187us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-05-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-05-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-05-310001275187us-gaap:FairValueMeasurementsRecurringMember2021-05-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberango:RevenueBasedPaymentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-08-310001275187us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberango:RevenueBasedPaymentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-08-310001275187srt:MinimumMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberango:RevenueBasedPaymentMemberango:MeasurementInputProbabilityofPaymentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-08-310001275187srt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberango:RevenueBasedPaymentMemberango:MeasurementInputProbabilityofPaymentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-08-310001275187us-gaap:CostOfSalesMember2021-06-012021-08-310001275187us-gaap:CostOfSalesMember2020-06-012020-08-310001275187us-gaap:ResearchAndDevelopmentExpenseMember2021-06-012021-08-310001275187us-gaap:ResearchAndDevelopmentExpenseMember2020-06-012020-08-310001275187us-gaap:SellingAndMarketingExpenseMember2021-06-012021-08-310001275187us-gaap:SellingAndMarketingExpenseMember2020-06-012020-08-310001275187us-gaap:GeneralAndAdministrativeExpenseMember2021-06-012021-08-310001275187us-gaap:GeneralAndAdministrativeExpenseMember2020-06-012020-08-31ango:patent0001275187ango:CrBardIncMember2012-01-112012-01-110001275187ango:TheDelawareActionMember2015-03-102015-03-100001275187ango:LegalCostsMember2021-06-012021-08-310001275187ango:LegalCostsMember2020-06-012020-08-310001275187ango:TransitionserviceagreementMember2021-06-012021-08-310001275187ango:TransitionserviceagreementMember2020-06-012020-08-310001275187ango:DivestitureMember2021-06-012021-08-310001275187ango:DivestitureMember2020-06-012020-08-310001275187us-gaap:OtherExpenseMember2021-06-012021-08-310001275187us-gaap:OtherExpenseMember2020-06-012020-08-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2021-05-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2021-06-012021-08-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2021-08-31
Table of Contents
    
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended August 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission file number 0-50761
AngioDynamics, Inc.
(Exact name of registrant as specified in its charter)
https://cdn.kscope.io/b0f6a927f98f90c391d8108201277677-ango-20210831_g1.gif
 
Delaware11-3146460
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

14 Plaza Drive, Latham, New York 12110
(Address of principal executive offices and zip code)
(518) 795-1400
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common stock, par value $.01ANGONASDAQ Global Select Market
Preferred Stock Purchase RightsNASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:
None
(Title of Class)


Table of Contents
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes      No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes      No  
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer   Accelerated filer 
Non-accelerated filer Smaller reporting company 
Emerging growth company
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date.
Class Outstanding as of September 28, 2021
Common Stock, par value $.01 38,650,434



Table of Contents
AngioDynamics, Inc. and Subsidiaries
TABLE OF CONTENTS
 
Page
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

2

Table of Contents
PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands of dollars, except per share data)
 
Three Months Ended
Aug 31, 2021Aug 31, 2020
Net sales$76,971 $70,216 
Cost of sales (exclusive of intangible amortization)36,832 34,452 
Gross profit40,139 35,764 
Operating expenses:
Research and development7,394 9,009 
Sales and marketing24,446 17,705 
General and administrative8,943 8,557 
Amortization of intangibles4,821 4,953 
Change in fair value of contingent consideration195 (657)
Acquisition, restructuring and other items, net2,440 1,319 
Total operating expenses48,239 40,886 
Operating loss(8,100)(5,122)
Other income (expense):
Interest expense, net(156)(215)
Other income (expense), net(352)524 
Total other income (expense), net(508)309 
Loss before income tax benefit(8,608)(4,813)
Income tax benefit(1,636)(545)
Net loss$(6,972)$(4,268)
Loss per share
Basic$(0.18)$(0.11)
Diluted$(0.18)$(0.11)
Weighted average shares outstanding
Basic38,734 38,157 
Diluted38,734 38,157 
The accompanying notes are an integral part of these consolidated financial statements.
3

Table of Contents
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in thousands of dollars)
 
Three Months Ended
Aug 31, 2021Aug 31, 2020
Net loss$(6,972)$(4,268)
Other comprehensive income, before tax:
Foreign currency translation 590 2,095 
Other comprehensive income, before tax590 2,095 
Income tax expense related to items of other comprehensive income (loss)  
Other comprehensive income, net of tax590 2,095 
Total comprehensive loss, net of tax$(6,382)$(2,173)
The accompanying notes are an integral part of these consolidated financial statements.

4

Table of Contents
AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)
Aug 31, 2021May 31, 2021
Assets
Current assets
Cash and cash equivalents$35,472 $48,161 
Accounts receivable, net of allowances of $1,864 and $1,919 respectively
35,416 35,405 
Inventories49,305 48,614 
Prepaid expenses and other11,128 8,699 
Total current assets131,321 140,879 
Property, plant and equipment, net41,133 37,073 
Intangible assets, net168,893 168,977 
Goodwill201,491 201,316 
Other assets12,925 13,193 
Total assets$555,763 $561,438 
Liabilities and stockholders' equity
Current liabilities
Accounts payable$22,687 $19,630 
Accrued liabilities26,892 35,459 
Other current liabilities2,518 2,495 
Total current liabilities52,097 57,584 
Long-term debt, net of current portion25,000 20,000 
Deferred income taxes18,397 19,955 
Contingent consideration, net of current portion15,936 15,741 
Other long-term liabilities8,383 8,701 
Total liabilities119,813 121,981 
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
  
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,390,241 and 38,920,951 shares issued and 39,020,241 and 38,550,951 shares outstanding at August 31, 2021 and May 31, 2021, respectively
379 377 
Additional paid-in capital576,380 573,507 
Accumulated deficit (138,838)(131,866)
Treasury stock, 370,000 shares at August 31, 2021 and May 31, 2021, respectively
(5,714)(5,714)
Accumulated other comprehensive income3,743 3,153 
Total Stockholders’ Equity435,950 439,457 
Total Liabilities and Stockholders' Equity$555,763 $561,438 
The accompanying notes are an integral part of these consolidated financial statements.
5

Table of Contents
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)
Three Months Ended
Aug 31, 2021Aug 31, 2020
Cash flows from operating activities:
Net loss$(6,972)$(4,268)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization6,997 6,577 
Non-cash lease expense602 666 
Stock based compensation2,429 1,864 
Change in fair value of contingent consideration195 (657)
Deferred income taxes(1,690)(620)
Change in accounts receivable allowances(44)460 
Fixed and intangible asset impairments and disposals30 90 
Other(46)(432)
Changes in operating assets and liabilities:
Accounts receivable(36)(2,706)
Inventories(670)7,247 
Prepaid expenses and other(3,354)(3,559)
Accounts payable, accrued and other liabilities(6,345)(10,087)
Net cash used in operating activities(8,904)(5,425)
Cash flows from investing activities:
Additions to property, plant and equipment(1,021)(1,824)
Additions to placement and evaluation units(4,471) 
Cash paid for acquisitions(3,600) 
Net cash used in investing activities(9,092)(1,824)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt5,000  
Proceeds from exercise of stock options and employee stock purchase plan446 491 
Net cash provided by financing activities5,446 491 
Effect of exchange rate changes on cash and cash equivalents(139)252 
Decrease in cash and cash equivalents(12,689)(6,506)
Cash and cash equivalents at beginning of period48,161 54,435 
Cash and cash equivalents at end of period$35,472 $47,929 
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period$162 $197 
The accompanying notes are an integral part of these consolidated financial statements.
6

Table of Contents
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands of dollars, except share data)

  
Common StockAdditional
paid in
capital
Accumulated deficit Accumulated
other
comprehensive
income
Treasury Stock
SharesAmountSharesAmountTotal
Balance at May 31, 202138,920,951 $377 $573,507 $(131,866)$3,153 (370,000)$(5,714)$439,457 
Net loss(6,972)(6,972)
Exercise of stock options80,635 1 1,279 1,280 
Issuance/Cancellation of restricted stock units279,495 (1,734)(1,734)
Issuance/Cancellation of performance share units59,371 — 
Purchases of common stock under ESPP49,789 1 899 900 
Stock-based compensation2,429 2,429 
Other comprehensive income, net of tax590 590 
Balance at August 31, 202139,390,241 $379 $576,380 $(138,838)$3,743 (370,000)$(5,714)$435,950 


Common StockAdditional
paid in
capital
Accumulated deficit Accumulated
other
comprehensive
income (loss)
Treasury Stock
SharesAmountSharesAmountTotal
Balance at May 31, 202038,448,536 $374 $561,871 $(100,318)$(1,341)(370,000)$(5,714)$454,872 
Net loss(4,268)(4,268)
Issuance/Cancellation of restricted stock units164,946 (143)(143)
Purchases of common stock under ESPP79,596 1 633 634 
Stock-based compensation1,864 1,864 
Other comprehensive income, net of tax2,095 2,095 
Balance at August 31, 202038,693,078 $375 $564,225 $(104,586)$754 (370,000)$(5,714)$455,054 

The accompanying notes are an integral part of these consolidated financial statements.
7

Table of Contents
AngioDynamics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Balance Sheet as of August 31, 2021, the Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three months ended August 31, 2021 and 2020, the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2021 and 2020 and the Consolidated Statements of Cash Flows for the three months ended August 31, 2021 and 2020 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2021 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three months ended August 31, 2021 and 2020 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, "us", "we" or the “Company”. All intercompany balances and transactions have been eliminated.
2. ACQUISITIONS
Camaro Support Catheter Asset Acquisition
On July 27, 2021, the Company acquired the Camaro support catheter asset from QX Medical, LLC for an aggregate purchase price of $4.0 million, which included an upfront payment of $3.6 million and $0.4 million in purchase price holdbacks, along with $1.0 million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory and fixed assets of $0.1 million and an intangible asset product technology of $3.9 million. The intangible asset will be amortized over 15 years. The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.
3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

Under ASC 606, Revenue from Contracts with Customers, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
The following table summarizes net sales by Global Business Unit ("GBU") and geography:
Three Months Ended Aug 31, 2021
Three Months Ended Aug 31, 2020
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Endovascular Therapies$34,753 $3,305 $38,058 $26,981 $2,876 $29,857 
Vascular Access20,476 4,481 24,957 19,222 8,883 28,105 
Oncology9,235 4,721 13,956 7,905 4,349 12,254 
Total$64,464 $12,507 $76,971 $54,108 $16,108 $70,216 
As the Company has previously announced, the Company is focused on its ongoing transformation from a company with abroad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and
8

Table of Contents
innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our high technology products including Auryon, Mechanical Thrombectomy (which includes AngioVac and thrombolytics) and NanoKnife. We will refer to these high technology product lines as our Med Tech business and we will refer to the remainder of the portfolio as our Med Device business.
The following table summarizes net sales by Med Tech and Med Device:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Net Sales
Med Tech$17,619 $10,486 
Med Device59,352 59,730 
Total$76,971 $70,216 
Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. The duration of these agreements are typically a year and the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an
9

Table of Contents
embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the three months ended August 31, 2021, such product returns were not material.
Contract Balances with Customers
A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying consolidated balance sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)Aug 31, 2021
May 31, 2021
Receivables$35,416 $35,405 
Contract assets$ $ 
Contract liabilities$462 $426 
During the three months ended August 31, 2021, the Company had additions to contract liabilities of $0.4 million. This was offset by $0.4 million in revenue that was recognized during the three months ended August 31, 2021.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.
10

Table of Contents

4. INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)Aug 31, 2021May 31, 2021
Raw materials$25,367 $22,925 
Work in process7,297 8,022 
Finished goods16,641 17,667 
Inventories$49,305 $48,614 
The Company periodically reviews inventory for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow-moving inventory. The total inventory reserve at August 31, 2021 and May 31, 2021 was $3.9 million and $3.8 million, respectively.
5. GOODWILL AND INTANGIBLE ASSETS
Goodwill
Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.
The Company's annual testing for impairment of goodwill was completed as of December 31, 2020. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.
Even though the Company determined that there was no goodwill impairment as of December 31, 2020, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2021.
There were no adjustments to goodwill for the three months ended August 31, 2021 other than foreign currency translation adjustments.
Definite Lived Intangible Assets
Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from two to eighteen years. The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
Intangible assets consisted of the following:
Aug 31, 2021
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$241,758 $(101,188)$140,570 
Customer relationships60,242 (35,119)25,123 
Trademarks9,950 (6,975)2,975 
Licenses6,087 (5,862)225 
$318,037 $(149,144)$168,893 
11

Table of Contents
May 31, 2021
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$236,907 $(97,343)$139,564 
Customer relationships60,291 (34,164)26,127 
Trademarks9,950 (6,905)3,045 
Licenses6,087 (5,846)241 
$313,235 $(144,258)$168,977 

Amortization expense for the three months ended August 31, 2021 and 2020 was $4.8 million and $5.0 million, respectively.
Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:
(in thousands)
Remainder of 2022$14,636 
202319,034 
202416,826 
202516,807 
202616,626 
2027 and thereafter84,964 
$168,893 
6. ACCRUED LIABILITIES
Accrued liabilities consisted of the following:
(in thousands)Aug 31, 2021May 31, 2021
Payroll and related expenses$11,214 $20,408 
Royalties1,616 2,663 
Accrued severance537 548 
Sales and franchise taxes819 631 
Outside services6,129 4,256 
Litigation Matters 975 
Rebates694 503 
Other5,883 5,475 
$26,892 $35,459 
12

Table of Contents

7. LONG-TERM DEBT
On June 3, 2019 the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lender's party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents.
The Credit Agreement provides for a $125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries.
The Credit Agreement has a five year maturity. Interest on the facility is based, at the Company’s option, on either a base rate of LIBOR or alternate base rate, plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility also carries a commitment fee of 0.20% to 0.25% per annum on the unused portion.
The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.
The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: 
Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.
* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the credit agreement included as an exhibit to Form 8-K filed on June 6, 2019.
As of August 31, 2021, there was $25.0 million outstanding on the Revolving Facility. As of August 31, 2021 and May 31, 2021, the carrying value of long-term debt approximated its fair market value.
The interest rate on the Revolving Facility at August 31, 2021 was 1.34%.

8. INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 10.6% as of the first quarter of fiscal year 2022, as compared to 14.2% for the same period in fiscal year 2021. In fiscal year 2022, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.
Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of August 31, 2021. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

13

Table of Contents

9. SHARE-BASED COMPENSATION
On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. As of August 31, 2021, there was a maximum of 1.7 million shares of common stock available for future grant under the 2020 Plan.
Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.
The Company also has an employee stock purchase plan. As of August 31, 2021, there was a maximum of 2.4 million shares of common stock available for future grant under the employee stock purchase plan.
For the three months ended August 31, 2021 and 2020, share-based compensation expense was $2.4 million and $1.9 million, respectively.
During the three months ended August 31, 2021 and 2020, the Company granted stock options and restricted stock units under the 2020 and 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.
During the three months ended August 31, 2021 and 2020, the Company granted performance share units under the 2020 and 2004 Plan to certain employees. The awards may be earned by achieving performance levels over the requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return (“TSR”) of the Company’s common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company’s common stock on the date of grant and use a Monte Carlo simulation model.
As of August 31, 2021, there was $22.4 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.
10. EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.
The following table reconciles basic to diluted weighted-average shares outstanding:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Basic38,734 38,157 
Effect of dilutive securities  
Diluted38,734 38,157 
Securities excluded as their inclusion would be anti-dilutive3,443 3,180 

11. SEGMENT AND GEOGRAPHIC INFORMATION
The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis utilizing various breakouts of the data including Global Business Unit, Med Tech versus Med Device and geography. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations,
14

Table of Contents
regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
The table below summarizes net sales by Global Business Unit:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Net Sales
Endovascular Therapies$38,058 $29,857 
Vascular Access24,957 28,105 
Oncology13,956 12,254 
Total$76,971 $70,216 
The table below summarizes net sales by Med Tech and Med Device:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Net Sales
Med Tech$17,619 $10,486 
Med Device59,352 59,730 
Total$76,971 $70,216 
The table below summarizes net sales by geographic area based on external customer location:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Net Sales
United States$64,464 $54,108 
International12,507 16,108 
Total$76,971 $70,216 
12. FAIR VALUE
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.
15

Table of Contents
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:
Fair Value Measurements using inputs considered as:
Fair Value at Aug 31, 2021
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$ $ $15,936 $15,936 
Total Financial Liabilities$ $ $15,936 $15,936 
Fair Value Measurements using inputs considered as:
Fair Value at May 31, 2021
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$ $ $15,741 $15,741 
Total Financial Liabilities$ $ $15,741 $15,741 
There were no transfers between Level 1, 2 and 3 for the three months ended August 31, 2021 and 2020.
The table below presents the changes in fair value components of Level 3 instruments:

Three Months Ended Aug 31, 2021
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2021
$15,741 
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration (1)
195 
Balance, August 31, 2021
$15,936 
(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.

Contingent Liability for Acquisition Earn Outs
Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.
The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements, which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2021:
(in thousands)Fair ValueValuation TechniqueUnobservable InputRange
Revenue based payments$15,936 Discounted cash flowDiscount rate5%
Probability of payment
66% - 100%
Projected fiscal year of payment2024 - 2025
16

Table of Contents
At August 31, 2021, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $20.0 million. The milestones, including revenue projections and technical milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2022 to 2029 in order for the associated consideration to be paid.

13. LEASES
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
The following table presents supplemental balance sheet information related to leases:
(in thousands)Balance Sheet LocationAug 31, 2021May 31, 2021
Assets
Operating lease ROU assetOther assets$8,773 $9,382 
Liabilities
Current operating lease liabilitiesOther current liabilities2,444 2,415 
Non-current operating lease liabilitiesOther long-term liabilities6,668 7,319 
Total lease liabilities$9,112 $9,734 
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
Aug 31, 2021
Weighted average remaining term (in years)3.90
Weighted average discount rate3.8 %
The maturities of the lease liabilities for each of the following fiscal years is:
(in thousands)Aug 31, 2021
Remainder of 2022$2,048 
20232,780 
20242,202 
20251,447 
20261,144 
2027 and thereafter171 
Total lease payments$9,792 
Less: Imputed Interest680 
Total lease obligations$9,112 
Less: Current portion of lease obligations2,444 
Long-term lease obligations$6,668 
17

Table of Contents
During the three months ended August 31, 2021 and 2020, the Company recognized $0.7 million and $0.9 million of operating lease expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows:
Three Months Ended
(in thousands)
Aug 31, 2021
Aug 31, 2020
Cost of sales$219 $201 
Research and development98 288 
Sales and marketing40 100 
General and administrative330 295 
$687 $884 
The following table presents supplemental cash flow and other information related to leases for the three months ended:
(in thousands)Aug 31, 2021Aug 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$682 $672 
ROU assets obtained in exchange for lease liabilities
Operating leases$ $487 
14. COMMITMENTS AND CONTINGENCIES    
Legal Proceedings
The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
C.R. Bard, Inc. v. AngioDynamics, Inc.
On January 11, 2012, C.R. Bard, Inc. ("Bard") filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 (“’302 Patent”), 7,959,615 (“’615 Patent”) and 7,947,022(“’022 Patent”)). The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO"). Following the reexamination proceedings, and the parties’ related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the ‘615 Patent were held invalid, while the remaining claims of the ‘615 Patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings. Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware ("District of Delaware"). A scheduling order was entered on March 23, 2021. The Company filed a Motion to Amend its Answer and Counterclaims on April 14, 2021. This motion seeks to add counterclaims for infringement of U.S. Patent Nos. 9,168,365; 9,895,523; and 10,632,295, as well as a counterclaim of inequitable conduct, and remains pending. On July 22, 2021, in another case against a different defendant the District of Utah invalidated multiple claims of the ‘302, ‘022, and ‘615 Patents under 35 USC §101, including claims asserted against the Company. Following the Utah court’s decision, the Company filed a Motion for Judgment on the Pleadings (which remains pending) based on collateral estoppel on August 9, 2021. Bard filed its opposition brief on September 2, 2021 and the Company filed a reply on September 9, 2021. The parties also filed a stipulation to stay all deadlines pending resolution of the Company’s Motion for Judgment on the Pleadings, which the Court entered on August 16, 2021. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The case proceeded through trial which began on March 4, 2019. At the close of Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On May 10, 2019, the Company filed a motion for attorney fees and non-taxable expenses under 35 USC Sec. 285. Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court’s invalidity and non-infringement judgments. The Company filed a combined Petition
18

Table of Contents
for rehearing and rehearing en banc on December 10, 2020, which was denied on January 15, 2021. The Federal Circuit issued its mandate on January 22, 2021. On March 15, 2021, the District of Delaware entered an order requiring the parties to submit status reports and denied as moot the Company’s motion for attorney’s fees and expenses. The parties submitted status reports on March 29, 2021 and the Court subsequently held two status conferences on July 27, 2021 and August 20, 2021. The parties agreed to schedule trial the week of May 9, 2022 and filed a joint letter indicating the same on September 3, 2021. The Court has not yet docketed the trial and the matter remains pending. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 (“’992”) and 9,603,993 (“’993”). On May 20, 2021, the Company filed a Motion to Dismiss Bard’s claims with respect to the ’992 and ’993 patents. On July 22, 2021, the Company submitted the Utah court’s decision invalidating claims of the related ‘302, ‘022, and ‘615 Patents as supplemental authority in support of its Motion to Dismiss. The parties agreed to submit supplemental briefing to address the Utah court’s decision. Bard submitted its brief on August 12, 2021, and the Company submitted its reply on September 2, 2021. The motion remains pending. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
AngioDynamics, Inc. v. C.R. Bard, Inc.
On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs. The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs. The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety. Bard made a motion for summary judgment which was denied in its entirety in a decision issued by the Court on May 5, 2021. Bard also raised a series of challenges targeted at one of AngioDynamics’ expert witnesses, which the Court denied in part and granted in part in decisions on May 5, 2021 and June 11, 2021. Discovery is largely complete, and trial is scheduled to commence on July 5, 2022.
15. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET
Acquisition, Restructuring and Other Items
Acquisition, restructuring and other items, net, consisted of:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Legal (1)
$2,084 $794 
Transition service agreement (2)
 (375)
Divestiture (3)
 273 
Other356 627 
Total$2,440 $1,319 
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.
(3) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.
19

Table of Contents

16. ACCUMULATED OTHER COMPREHENSIVE INCOME
Changes in each component of accumulated other comprehensive income, net of tax, are as follows:
Three Months Ended Aug 31, 2021
(in thousands)Foreign currency translation income
Balance at May 31, 2021
$3,153 
Other comprehensive income before reclassifications, net of tax590 
Net other comprehensive income$590 
Balance at August 31, 2021
$3,743 
17. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Pronouncements - Adopted
There are no recently issued accounting pronouncements that have been adopted.
Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
There are no new accounting pronouncements issued that are expected to have a material impact on our consolidated financial statements.

20

Table of Contents
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q. The following discussion should be read in conjunction with the Company's 2021 Annual Report on Form 10-K, and the consolidated financial statements and notes thereto included elsewhere in the Form 10-Q.
Disclosure Regarding Forward-Looking Statements
This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from our expectations, expressed or implied. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, our ability to integrate purchased businesses and other factors including natural disasters and pandemics (such as the scope, scale and duration of the impact of COVID-19). Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC").
Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics disclaims any obligation to update the forward-looking statements. 
Disclosure Regarding Trademarks
This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames. For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP. Information on our website or connected to our website is not incorporated by reference into this Quarterly Report on Form 10-Q.
Executive Overview
We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.
Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy.
Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions of our product offerings are created through internal and external product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and selective business development opportunities to provide growth opportunities.
21

Table of Contents
We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of direct sales and distributor relationships. Our end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally.
The COVID-19 global pandemic has impacted our business and may pose future risks. Even with the public health actions that have been taken to reduce the spread of the virus, there may continue to be disruptions with respect to consumer demand, hospital operating procedures and workflow, our ability to continue to manufacture products, the reliability of our supply chain and inflation. Accordingly, management continues to evaluate the Company’s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance.
In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three months ended August 31, 2021 compared to the three months ended August 31, 2020 are as follows:

Three months ended August 31, 2021:

Revenue increased by 9.6% to $77.0 million.
Gross profit increased 120 bps to 52.1%.
Net loss increased by $2.7 million to $7.0 million.
Loss per share increased by $0.07 to a loss of $0.18

Our Med Tech business, comprised of Mechanical Thrombectomy, Auryon and NanoKnife, experienced improved performance during the first quarter of fiscal year 2022 as the number of procedures continued to improve from the COVID-19 impact in the first quarter of the prior year. In our Med Device business, Vascular Access, excluding the large prior year order in the UK, also improved in the first quarter of fiscal year 2022 compared to the prior year period. This was partially offset by our Med Device Oncology products, which continued to face pressure from reductions in procedure volumes due to challenges resulting from the COVID-19 pandemic.
New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 17 to our consolidated financial statements in this Quarterly Report on Form 10-Q.
Results of Operations for the Three Months Ended August 31, 2021 and 2020
For the three months ended August 31, 2021, the Company reported a net loss of $7.0 million, or a loss of $0.18 per diluted share, on net sales of $77.0 million, compared with a net loss of $4.3 million, or a loss of $0.11 per diluted share, on net sales of $70.2 million during the same quarter of the prior year.
Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts, rebates and returns.

The table below summarizes net sales by Med Tech and Med Device:
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020% Change
Net Sales
Med Tech$17,619 $10,486 68.0%
Med Device59,352 59,730 (0.6)%
Total$76,971 $70,216 9.6%
22

Table of Contents
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020% Change
Net Sales by Global Business Unit
       Endovascular Therapies$38,058 $29,857 27.5%
       Vascular Access24,957 28,105 (11.2)%
       Oncology13,956 12,254 13.9%
            Total$76,971 $70,216 9.6%
Net Sales by Geography
       United States$64,464 $54,108 19.1%
       International12,507 16,108 (22.4)%
           Total$76,971 $70,216 9.6%
For the three months ended August 31, 2021, net sales increased $6.8 million to $77.0 million compared to the same period in the prior year.
The Med Tech business increased $7.1 million from the first quarter of the prior year. This growth was driven by Auryon sales which grew $4.8 million compared to the prior year. The AngioVac business grew $0.7 million as the Company generally continued to see consistent case volumes in AngioVac despite continued COVID-19 challenges. Additionally, NanoKnife also had improved capital and disposable sales which increased $1.0 and $0.7 million, respectively. NanoKnife capital growth was in the U.S and Europe while the disposable growth was driven by U.S sales.

The Med Device business net sales decreased $0.4 million from the prior year; however, excluding the large prior year order in the UK, net sales increased $4.8 million. This increase was driven by increased case volume compared to the first quarter of the prior year which resulted in increased sales of Core, Venous and BioSentry products of $2.1 million, $0.6 million and $0.4 million, respectively. Excluding the prior year order in the UK, Midlines, PICCs and Ports increased $2.2 million, with $1.1 million of the increase driven by U.S port sales. These increases were partially offset by decreased Microwave sales of $0.4 million.

Gross Profit, Operating expenses, and Other income (expense)
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020% Change
Gross profit$40,139 $35,764 12.2 %
Gross profit % of sales52.1 %50.9 %
Research and development$7,394 $9,009 (17.9)%
% of sales9.6 %12.8 %
Selling and marketing$24,446 $17,705 38.1 %
% of sales31.8 %25.2 %
General and administrative$8,943 $8,557 4.5 %
% of sales11.6 %12.2 %

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $4.4 million compared to the prior year. The change is primarily attributable to the following:
    
Sales volume positively impacted gross profit by $4.2 million year over year;
Sales mix positively impacted gross profit by $0.7 million as a result of increased sales of NanoKnife, Auryon and AngioVac;
Increased Auryon start up costs related to placed units of $1.0 million negatively impacted gross profit year over year; and
23

Table of Contents
Inflationary costs on raw materials, labor and freight had a negative impact of $1.4 million year over year, partially offset by favorablility in production volume and other initiatives of $1.2 million and $0.4 million, respectively.

Research and development expense - Research and development (“R&D”) expense includes internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense decreased $1.6 million compared to the prior year. The change is primarily attributable to the following:

R&D project expense decreased $1.0 million year over year primarily due to the timing of certain projects; and
Compensation and benefits expense decreased $0.4 million as a result of open roles.

Sales and marketing expense - Sales and marketing (“S&M”) expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $6.7 million compared to the prior year. The change is primarily attributable to the following:

Compensation and benefits expense increased $4.3 million due to additional headcount from the build-out of the Auryon sales and marketing teams; and
Travel and other expenses increased $2.5 million as some COVID-19 restrictions were lifted.

General and administrative expense - General and administrative (“G&A”) expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased $0.4 million compared to the prior year. The change is primarily attributable to the following:

Compensation and benefits expense increased $0.9 million year over year primarily due to increased headcount; and
Outside consultant spend decreased $0.7 million, partially offsetting the foregoing increase.
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020$ Change
Amortization of intangibles$4,821 $4,953 $(132)
Change in fair value of contingent consideration$195 $(657)$852 
Acquisition, restructuring and other items, net$2,440 $1,319 $1,121 
Other income (expense), net$(508)$309 $(817)

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

Amortization expense decreased $0.1 million from the prior year due to assets that became fully amortized in fiscal year 2021 along with the write-off of the OARtrac intangible asset in the fourth quarter of fiscal year 2021. This was partially offset by amortization relating to the Camaro intangible asset addition of $3.9 million in the first quarter of fiscal year 2022.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

The change in the fair value is related to the Eximo contingent consideration.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net, increased by $1.1 million compared to the prior year. The change is primarily attributable to the following:

24

Table of Contents
Legal expense, related to litigation that is outside of the normal course of business, of $2.1 million was recorded in the first quarter of fiscal year 2022 compared to $0.8 million in the prior year;
In the first quarter of fiscal year 2021, and as a result of the sale of the Fluid Management business, the Company incurred $0.3 million of expense to move manufacturing facilities and the Company received $0.4 million from Medline Industries, Inc. as part of the TSA agreement. These activities were completed during fiscal year 2021; and
Other expenses of $0.4 million in the first quarter of fiscal year 2022 compared to $0.6 million in the prior year consisted mainly of severance associated with organizational changes.

Other income (expense), net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

The increase in other expense from the prior year of $0.8 million is primarily due to unrealized foreign currency losses of $0.9 million.

Income Tax Benefit
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Income tax benefit$(1.6)$(0.5)
Effective tax rate including discrete items19.0 %11.3 %

Our effective tax rate including discrete items for the three-month periods ended August 31, 2021 and 2020 was 19.0% and 11.3%, respectively. In fiscal year 2022, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).
The estimated annual effective tax rate, however, prior to discrete items was 10.6% in the first quarter of fiscal year 2022, as compared to 14.2% for the same period in fiscal year 2021.
Liquidity and Capital Resources
We regularly review our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic. We believe that our current cash on hand and availability under our Revolving Facility provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. We are closely monitoring receivables and payables.
Our cash and cash equivalents totaled $35.5 million as of August 31, 2021, compared with $48.2 million as of May 31, 2021. As of August 31, 2021 and May 31, 2021, total debt outstanding related to the Revolving Facility was $25.0 million and $20.0 million, respectively. The fair value of contingent consideration liability as of August 31, 2021 and May 31, 2021, was $15.9 million and $15.7 million, respectively.
The table below summarizes our cash flows:<
Three Months Ended
(in thousands)Aug 31, 2021Aug 31, 2020
Cash provided by (used in):
Operating activities$(8,904)$(5,425)
Investing activities(9,092)(1,824)
Financing activities5,446 491 
Effect of exchange rate changes on cash and cash equivalents(139)252 
Net change in cash and cash equivalents$